Technical Analysis for CORT - Corcept Therapeutics Incorporated

Grade Last Price % Change Price Change
grade F 10.2 -3.77% -0.40
CORT closed down 3.77 percent on Wednesday, May 22, 2019, on 79 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CORT trend table...

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -3.77%
Oversold Stochastic Weakness -3.77%
Down 3 Days in a Row Weakness -3.77%
Oversold Stochastic Weakness -3.77%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.08%
Outside Day Range Expansion -6.08%
Oversold Stochastic Weakness -6.08%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -6.16%
Narrow Range Bar Range Contraction -6.16%

Older signals for CORT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also involved in an on-going Phase III study of mifepristone, the active ingredient in Korlym, for treatment of the psychotic features of psychotic depression. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Pharmaceutical Surgery Organ Systems Disorders Endocrine System Hormones Diabetes Mellitus Depression Cushing's Syndrome Corcept Therapeutics Hyperglycemia Cortisol Endogenous Cushing's Syndrome
Is CORT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 20 Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation
May 13 CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & Grossman, LLC Class Action
May 13 DEADLINE MONDAY REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 13 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, HCSG, BA and NOK
May 13 DEADLINE TODAY: Rosen Law Firm Reminds Corcept Therapeutics Incorporated Investors of Important May 13th Deadline in Securities Class Action Lawsuit - CORT
May 12 INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In NIO, CORT, HCSG or FCHS To Contact The Firm
May 10 The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, FSNN and BSX
May 10 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
May 10 CLASS ACTION UPDATE for CORT, FSNN and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
May 10 DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Corcept Therapeutics Incorporated and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
See more CORT news...
Indicators
Indicator Value
52 Week High 20.0
52 Week Low 9.14
Average Volume 773,164
200-Day Moving Average 12.8447
50-Day Moving Average 11.7326
20-Day Moving Average 11.5235
10-Day Moving Average 10.763
Average True Range 0.4199
ADX 22.38
+DI 13.5324
-DI 32.6376
Chandelier Exit (Long, 3 ATRs ) 11.6103
Chandelier Exit (Short, 3 ATRs ) 11.4497
Upper Bollinger Band 13.1475
Lower Bollinger Band 9.8995
Percent B (%b) 0.09
BandWidth 28.185881
MACD Line -0.4174
MACD Signal Line -0.2766
MACD Histogram -0.1408
Fundamentals Value
Market Cap 1.15 Billion
Num Shares 113 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 51.00
Price-to-Sales 19.04
Price-to-Book 31.30
PEG Ratio 0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.86
Resistance 3 (R3) 10.93 10.78 10.75
Resistance 2 (R2) 10.78 10.61 10.75 10.71
Resistance 1 (R1) 10.49 10.51 10.42 10.42 10.68
Pivot Point 10.34 10.34 10.30 10.31 10.34
Support 1 (S1) 10.05 10.17 9.98 9.98 9.72
Support 2 (S2) 9.90 10.07 9.87 9.69
Support 3 (S3) 9.61 9.90 9.65
Support 4 (S4) 9.54